{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360011143909775232.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1097/bor.0b013e3282f05b63"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/10.1097/BOR.0b013e3282f05b63"}}],"dc:title":[{"@value":"Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380011143909775233","@type":"Researcher","foaf:name":[{"@value":"Dimitrios Vassilopoulos"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011143909775232","@type":"Researcher","foaf:name":[{"@value":"Leonard H Calabrese"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10408711"}],"prism:publicationName":[{"@value":"Current Opinion in Rheumatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2007-11","prism:volume":"19","prism:number":"6","prism:startingPage":"619","prism:endingPage":"625"},"reviewed":"false","url":[{"@id":"https://journals.lww.com/10.1097/BOR.0b013e3282f05b63"}],"createdAt":"2007-10-04","modifiedAt":"2025-01-21","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1097/bor.0b013e3282f05b63"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_2kXJyTVm73lSfNkXS8Fb1XxpRBH"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_2kXJyTVm73lSfNkXS8Fb1XxpRBH"}]}